Report highlights Chinese pharma market potential

A new study on the Chinese pharmaceutical market, the CPhI Annual Report, highlights an increase in active pharmaceutical ingredients (API) manufacturing, innovation, competitiveness and finished product manufacturing.

The analysis finds that industry efforts to align standards closer to European and US Food and Drug Administration standards have been recognized, with an improvement in the industry’s reputation.

CPhI indicates that “rigorous reformation efforts” by the newly-formed National Medical Products Administration (NMPA), the successor to the China Food and Drug Administration (CFDA), are partly responsible for the change.